Evaluation of serogroup C and ACWY meningococcal vaccine programs: Projected impact on disease burden according to a stochastic two-strain dynamic model  by Vickers, David M. et al.
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Objective:  Advisory  committees  in  Canada  and  the  United  States  have  updated  recommendations  for
quadrivalent  meningococcal  conjugate  vaccines  against  serogroups  A, C,  W135,  and  Y.  Our objective  was
to evaluate  optimally  effective  meningococcal  vaccination  policies  using  a stochastic  dynamic  model.
Canada  was  used  as  an  example.
Methods:  Our  stochastic  dynamic  model  of  Neisseria  meningitidis  (Nm)  transmission  in an age-structured
population  assumed  partial  cross-immunity  among  two aggregated  serogroup  categories:  ‘AWY’  con-
taining  A, W135,  and  Y; and  ‘Other’  containing  B, C,  and  ungroupable  types.  We  compared  the  impact  of
monovalent  C  versus  quadrivalent  ACWY  vaccination  on Nm  carriage  and  invasive  meningococcal  dis-
ease  (IMD).  Our  model  was  parameterized  with  Canadian  epidemiological  and  demographic  data  and
employed  probabilistic  sensitivity  analysis.mmunization programs
tochastic model
train replacement
Results: Routine  infant  immunization  at 12  months  and  boosting  at 15  years  with  a quadrivalent  vaccine  is
projected  to have  the largest  impact  on  total  IMD incidence:  a 74%  reduction  over  40 years.  Routine  infant
immunization  with  a monovalent  vaccine  at 12  months  only  has  much  less  impact  and  also  generates
strain  replacement  appearing  after  approximately  ten  years  of  continuous  use.
Conclusions:  Immunizing  infants  at 12  months  and boosting  adolescents  at 15  years  with  an  ACWY  vaccine
fectivis predicted  to be most  ef
. Introduction
Neisseria meningitidis (Nm) is an important cause of meningitis
nd septicemia worldwide [1]. Although the epidemiology of inva-
ive meningococcal disease (IMD) varies globally, nearly all disease
s caused by serogroups A, B, C, W135, X, and Y [2]. While devastat-
ng epidemics of IMD  continually occur in the ‘meningitis belt’ of
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sub-Saharan Africa, elsewhere (e.g., Europe, the United States, and
Canada), IMD  incidence is less than 10 per 100,000 population per
year [2,3].
Despite the public health importance of Nm as a pathogen, it
is widely regarded as a commensal of the respiratory tract [3].
IMD  is a rare consequence of infection that occurs when Nm bacte-
ria colonizing the mucosal surfaces of the nasopharynx penetrate
the mucosal tissue and invade the bloodstream, causing menin-
gitis and fulminant septicemia [3] or other complications [4]. In
Europe and North America, the peak of carriage is observed in
teenagers and young adults, and the peak of disease in young
infants, with a second peak of lower magnitude in teenagers [1].
Asymptomatic nasopharyngeal infections engender development
of immunity both at the individual level (direct protection) and the
population level (herd protection). However, the exact nature and
mechanisms of naturally acquired immunity are not completely
understood [5].
reserved.
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Fig. 1. Model diagram. S: susceptible; CAWY (CO): carrying ‘AWY’ (‘Other’); CAWY;O (CO;AWY): carrying ‘AWY’ while immune to ‘Other’ (‘Other’ while immune to ‘AWY’); RAWY (RO,
RAWYO): immune to ‘AWY’ (‘Other’, both); XAWY (XO): IMD  due to ‘AWY’ (‘Other’); V
S
mono (V
S
quad): vaccine immunity due to C vaccine (ACWY vaccine); blue transitions represent
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Nnfection and recovery to natural immunity; yellow represents loss of natural imm
accine  immunity or loss of vaccine immunity for the ACWY vaccine; gray represen
epresents recovery from IMD  to a state of natural immunity. Corresponding param
Current control strategies are aimed at reducing transmission,
reventing IMD, and enhancing host resistance [4]. Recent progress
n preventing and controlling IMD  has beneﬁtted from the intro-
uction of monovalent conjugate vaccines against serogroup C.
ince being adopted, many countries have experienced a substan-
ial decline in serogroup C disease [2]. Since 2001, Canada’s National
dvisory Committee on Immunization (NAC) has recommended
eningococcal C conjugate vaccine (‘C vaccine’) for infants through
o young adults. This has signiﬁcantly reduced serogroup C IMD
ncidence, especially in populations where vaccine uptake was
arly and widespread [6].
However, concerns have arisen over vaccine-induced ‘strain
eplacement’, where control of one serogroup creates an empty
cological niche than can be ﬁlled by other serogroups [7].
ultivalent vaccines may  potentially be more likely to pre-
ent strain replacement. In 2007, NACI recommended use of
uadrivalent conjugate meningococcal vaccines for serogroups A,
, Y and W135 (‘ACWY vaccine’) for the control of outbreaks
aused by A, Y, or W135; close contacts of IMD  cases caused
y these serogroups; immunization of those aged 2–55 years
n certain high-risk groups; and routine immunization of ado-
escents in jurisdictions where local epidemiology warrants it
8].
The unpredictable nature of IMD  outbreaks and its rapidly
rogressing symptoms create signiﬁcant public concern as well
s disease management challenges. Moreover, herd immunity is
hought to be important in Nm epidemiology [6] and routine and
utbreak interventions are costly, meaning decision-makers must
onsider competing healthcare priorities. Under these circum-
tances, dynamic models can help us understand the complexity
f Nm epidemiology and the impact of policy decisions regarding
eningococcal vaccines.
Several seminal dynamic models have enhanced our under-
tanding of Nm disease dynamics [2,3,9,10]. However, multi-strain
m transmission models, as needed to predict strain replacement,; red transitions represent development of IMD; black represents development of
elopment of vaccine immunity or loss of vaccine immunity for the C vaccine; green
occur next to each arrow; see Supplementary File, Tables S1 and S2 for details.
are rare [3]. Here, we  develop a dynamic model to study the
potential impact of a quadrivalent ACWY vaccine compared to a
monovalent C vaccine. The Canadian setting was  selected based on
availability of data to calibrate the model.
2. Methods
2.1. Model
Our stochastic two-strain model allows us to capture the
effect of meningococcal vaccination on Nm epidemiology in a het-
erogeneous bacterial population where infection confers partial
cross-protection. The model aggregates multiple serogroups into
two larger groups: one contains A, W135, and Y (‘AWY’), while the
other contains B, C, and all other serogroups (‘Other’). Aggregat-
ing kept the number of model equations at a manageable level,
which is particularly important when natural immunity and cross-
protection are included. We  explored the impact of grouping using
sensitivity analysis.
The population is subdivided into discrete age classes (<1 year,
1 year, 2 years, 3 years,.  . .,  19 years, 20–29 years, 30–39 years,.  . .,
50–59 years, 60+ years). The ﬁrst twenty age classes are individual
birth cohorts and the last 5 age classes are aggregates of ten con-
secutive birth cohorts. At the end of each year, individuals in the
ﬁrst twenty age classes move to the next highest age class, whereas
one-tenth of individuals in each of the ﬁve aggregated age classes
move to the next highest age class. Newly born individuals enter
the <1 age class. Individuals are removed each year according to
age-speciﬁc all-cause mortality rates.
The model incorporates disease transmission mechanisms,
including age-speciﬁc contact rates. In the model diagram (Fig. 1),
compartment S is the number of susceptible individuals, CAWY
is the number infected by (carrying) serogroups A, W135, or Y
(‘AWY’), CO is the number carrying ‘Other’ serogroups, and XAWY
and XO are the number of individuals with invasive meningococcal
2 accine 33 (2015) 268–275
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Table 1
The ten vaccine scenarios examined. ‘C’ = monovalent C vaccine,
‘ACWY’ = quadrivalent ACWY vaccine.
Scenario Simulation time at which vaccination is introduced (year) and
age  of vaccination
t = 40 t = 50
1 C at 12 months C at 12 months
2  C at 12 years C at 12 years
3  C at 12 months ACWY at 12 months
4  C at 12 years ACWY at 12 years
5  C at 12 months ACWY at 12 months + ACWY at 12 years
6  C at 12 months ACWY at 12 months + ACWY at 15 years
7  C at 12 months C at 12 months + C at 12 years
8  C at 12 months C at 12 months + C at 15 years70 D.M. Vickers et al. / V
isease (IMD) attributable to ‘AWY’ or ‘Other’ respectively. ‘AWY’
nd ‘Other’ compete for the same pool of susceptible hosts, cre-
ting the potential for strain replacement once immunization is
ntroduced. We  assumed that carriage of one group fully protects
gainst co-infection by the other group [3].
Many individuals who clear Nm infection appear to have some
egree of natural immunity [5]. Therefore we deﬁne RAWY and
O as the number of individuals who have cleared infection and
ave natural immunity to ‘AWY’ and ‘Other’ respectively. We
oreover assumed that natural immunity to one group reduces
usceptibility to future infection by the other group, due to par-
ial cross-protection [5,11,12]; AWY is the relative susceptibility to
AWY’ infection for an individual with natural immunity to ‘Other’
ue to previous infection by ‘Other’. Thus, AWY = 1 corresponds to
omplete cross-immunity, whereas AWY = 0 corresponds to none.
O is deﬁned similarly.
CO|AWY and CAWY|O are the number of individuals carrying ‘Other’
respectively, ‘AWY’) who previously cleared infection by ‘AWY’
respectively, ‘Other’), and RAWYO is the number of individuals who
ave cleared infection and have natural immunity to both groups
f strains. We  assume the duration of carriage is constant across
erogroup and age.
Vmono is the number of individuals with vaccine-generated
mmunity to infection by ‘Other’ (due to C vaccine) and Vquad is the
umber of individuals with vaccine-generated immunity to infec-
ion by ‘Other’ or ‘AWY’ (due to the ACWY vaccine). We  assume
accine immunity works in all-or-none fashion; the vaccine pro-
ides no additional protection against IMD, above and beyond
rotection against infection; in other words, for a vaccine efﬁcacy
f 97%, 97% of those vaccinated will not contract IMD  or carry the
athogen, but 3% of those vaccinated are as likely to develop IMD
pon infection as an unvaccinated person. We  also assumed that
atural and vaccine-induced immunity affect carriage acquisition
ut not its duration.
The C vaccine only protects against infection (both carriage and
MD) by serogroup C. Hence, vaccine efﬁcacy against infection by
Other’ was assumed to be partial, and was determined by weight-
ng the vaccine efﬁcacy against C by the relative proportion of IMD
aused by C, B and other non-groupable Nm bacteria. This left a pro-
ortion of individuals in the susceptible compartment to account
or B infections. Vaccine efﬁcacy for ACWY vaccine against infec-
ion (both carriage and IMD) was weighted similarly since it does
ot protect against infection by serogroup B. Efﬁcacious vaccination
ith the C vaccine was assumed to provide no protection against
nfection by ‘AWY’, hence, those compartments were treated as
ully susceptible with respect to ‘AWY’ infection. However, indi-
iduals efﬁcaciously vaccinated with ACWY vaccine were protected
gainst both ‘AWY’ and ‘Other’.
The model was updated in discrete time steps. A description
f the state transitions appears in Table S1 of the Supplementary
ile. Both entrance into the carriage state and acquisition of IMD
ere modeled as stochastic processes, with number of stochastic
ransitions per time step sampled from a binomial distribution [13],
hile all other transitions were modeled deterministically. We  ana-
yzed a variant where all transitions were stochastic to conﬁrm that
he dynamics were unchanged. The model was coded in Matlab
2011a, and the code is provided in the Supplementary Files.
.2. Parameterization and model calibration
Parameter values were derived from epidemiological literature
r calibrated, except for the duration of natural immunity for which
 baseline assumption of two years was made (Supplementary
ile: Table S2) [1,14–26]. Each parameter value associated with
he natural history of infection or vaccination was estimated from9  C at 12 months C at 12 months + ACWY at 12 years
10 C at 12 months C at 12 months + ACWY at 15 years
key epidemiological or review articles in the available literature
between 1985 and 2011 [17,22].
Age-speciﬁc susceptibility to infection (AWYi and 
O
i ) and
degree of pathogenicity (εO and εAWY) were estimated through
model calibration to available IMD  case notiﬁcation and carriage
prevalence data (Supplementary File: Tables S2 and S3). The total
transmission rate is the product of age-speciﬁc contact rates ij
[26], age-speciﬁc susceptibility  i, and a constant transmission rate
coefﬁcient  ˇ (see Supplementary File for details).
To evaluate the impact of data uncertainty, triangular distribu-
tions were assumed for the least certain parameters: the calibrated
degree of pathogenicity (εO and εAWY), calibrated degree of suscep-
tibility to infection (AWYi and 
O
i ), rate of loss of natural immunity
(˛ON, ˛
AWY
N and ˛
AWYO
N ), and strength of cross-protection (AWY and
O).
A large number of Monte Carlo realizations were simulated: for
each realization, parameter values were drawn from these distri-
butions and the model was simulated with these parameter values.
The projected IMD  incidence and prevalence of carriage due to
‘Other’ and ‘AWY’ were generated in 5-year age groups (0–4, 5–9,
10–14, 15–19 and 20+). Minimum and maximum acceptable IMD
incidence and carriage prevalence due to ‘Other’ and ‘AWY’ were
deﬁned for each of these age groups. Any parameter set giving rise
to projections falling outside of one or more of the 20 acceptabil-
ity ranges was rejected. The 400 surviving parameter sets (out of
∼40,000 tested) were used to generate model results. Acceptability
ranges and triangular distribution bounds appear in Supplementary
File: Tables S2 and S3.
2.3. Vaccine scenarios
Vaccination was administered under ten scenarios (Table 1).
Assuming a country with a C vaccine program already in place,
all scenarios used the C vaccine exclusively in the ﬁrst 10 years
of the program (from t = 40 to 49 years). At t = 50 years, the ‘sta-
tus quo’ scenarios 1 and 2 continue with the same program, but
scenarios 3–10 involve a change in vaccine type and/or protocol.
This involved switching at least one dose from C vaccine to ACWY
vaccine (scenarios 3–6, 9, 10), adding a booster dose at age 12 or
15 years (scenarios 5–10), or both (scenarios 5, 6, 9, 10). Based on
recent coverage rates in Quebec [27,28], infant vaccination cover-
age was  90% and adolescent coverage was 80%.
3. ResultsIntroducing either vaccine has a marked effect on Nm epidemiol-
ogy. Introducing C vaccine at 12 months of age (scenario 1) quickly
causes a decline in prevalence of carriage of ‘Other’ (Fig. 2a and
Table 2) as well as IMD  incidence due to ‘Other’ serogroups (Fig. 2b).
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Fig. 2. Model projections for scenario 1: infant only vaccination using the C vaccine, starting at t = 40 years. (a) Overall prevalence of Nm carriage due to ‘Other’, (b) overall
incidence of IMD  due to ‘Other’, (c) overall prevalence of Nm carriage due to ‘AWY’, (d) overall incidence of IMD  due to ‘AWY’, (e) age-stratiﬁed prevalence of Nm carriage
due  to ‘Other’, (f) age-stratiﬁed incidence of IMD  due to ‘Other’, (g) age-stratiﬁed prevalence of Nm carriage due to ‘AWY’, (h) age-stratiﬁed incidence of IMD  due to ‘AWY’.
For  plots (a–d), black lines represent the average of 400 Monte Carlo realizations, while the gray lines bound 2 standard deviations, but insets in subpanels (b) and (d) show
results  for a single Monte Carlo realization. For plots (e–h), lines represent the average of 400 Monte Carlo realizations among those age 0–4 years (blue line), 5–9 years (red
line),  10–14 years (yellow line), 15–19 years (orange line), and ≥20 years (green line). The carriage time series appears smooth because we present the average of many
stochastic realizations.
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Table 2
Projected total IMD  incidence under all vaccine program scenarios and across all age classes.a
Scenario t = 40 t = 50 t = 60 t = 75 t = 90
1 0.92 (0.45, 1.4) 0.77 (0.38, 1.17) 0.77 (0.36, 1.17) 0.77 (0.36, 1.17) 0.76 (0.35, 1.17)
2  0.91 (0.45, 1.36) 0.78 (0.37, 1.19) 0.78 (0.36, 1.19) 0.79 (0.36, 1.23) 0.79 (0.35, 1.23)
3  0.9 (0.44, 1.36) 0.78 (0.37, 1.19) 0.66 (0.27, 1.05) 0.62 (0.25, 0.99) 0.6 (0.24, 0.97)
4  0.9 (0.44, 1.36) 0.78 (0.36, 1.21) 0.65 (0.26, 1.04) 0.6 (0.19, 1.01) 0.59 (0.15, 1.02)
5  0.9 (0.44, 1.36) 0.78 (0.39, 1.17) 0.46 (0.13, 0.79) 0.33 (0, 0.65) 0.3 (−0.04, 0.63)
6  0.9 (0.44, 1.36) 0.77 (0.38, 1.16) 0.39 (0.11, 0.67) 0.26 (−0.01, 0.54) 0.23 (−0.06, 0.52)
7  0.91 (0.45, 1.36) 0.77 (0.36, 1.17) 0.66 (0.3, 1.02) 0.67 (0.27, 1.06) 0.67 (0.29, 1.05)
8  0.9 (0.43, 1.36) 0.77 (0.37, 1.18) 0.62 (0.27, 0.97) 0.64 (0.28, 1) 0.65 (0.28, 1.03)
9  0.9 (0.43, 1.37) 0.77 (0.38, 1.16) 0.53 (0.22, 0.85) 0.44 (0.11, 0.77) 0.42 (0.05, 0.8)
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i10  0.9 (0.46, 1.34) 0.76 (0.38, 1.15) 
a IMD  incidence (per 100,000 population per year) due to ‘Other’ or ‘AWY’ serogro
tochastic realizations.
his decline is particularly strong and rapid in 0–4 year-olds, but is
lso observed in other ages also due to herd immunity (Fig. 2e and
).
However, C vaccine causes strain replacement: both IMD  inci-
ence and carriage prevalence due to ‘AWY’ increase after vaccine
ntroduction (Fig. 2c and d and Table 3), and this occurs across all
ges (Fig. 2g and h). However, the increase in ‘AWY’ IMD  is delayed
elative to the sudden decrease in ‘Other’ IMD: while IMD incidence
ue to ‘Other’ decreases immediately after introduction of C vac-
ine (t = 40 years), IMD  incidence due to ‘AWY’ does not begin to
ncrease signiﬁcantly until 10 years later (t = 50 years) and it takes
onger to reach equilibrium. Moreover, in a single model realization,
his effect is not obvious until much later than t = 50 years, due to
he stochastic nature of IMD  outbreaks (Fig. 2b and d insets). Hence,
he model suggests that there will be a signiﬁcant delay before we
bserve evidence of A, W135, or Y strain replacement in IMD  case
otiﬁcations (∼10 years after C vaccination becomes widespread)
lthough changes in carriage prevalence might be noticed sooner.
his is consistent with Canadian data over the past ten years [6].
Despite strain replacement, total IMD  incidence is lower under
 C vaccine program providing a single dose at 12 months (sce-
ario 1). However, these declines are relatively modest: total IMD
ncidence declines from 0.92 to 0.76/100,000/year over the long
erm (Table 2). In contrast, total IMD  incidence declines much more
igniﬁcantly when switching to ACWY vaccine at t = 50 years and
dding a second dose at 12 years of age (scenario 5): from 0.9 to
.3/100,000/year over the long term (Table 2). Strain replacement
s also prevented (Fig. 3).
As expected, strategies with multiple-scheduled vaccinations
nd/or CAWY vaccine were most effective. Model predictions for
hese strategies extend the general picture emerging from the com-
arison of Figs. 2 and 3 (Tables 2 and 3). Scenarios that add a booster
ose at 12/15 years and switch to ACWY vaccine for adolescent
mmunization and possibly also infant immunization reduce total
MD  incidence the most, as well as IMD  incidence due to ‘AWY’ and
Other’ individually (scenarios 5, 6, 9, 10: Tables 2 and 3). The best
verall approach is adding a booster dose at age 15 and switch-
ng to ACWY vaccine for both infants and adolescents (scenario 6).
cenarios that switch to ACWY vaccine without adding a second
ose at 12/15 years (scenarios 3, 4), or continue with C vaccine
ut add a second dose at 12/15 years (scenarios 7, 8), moderately
educe IMD  incidence. Finally, scenarios that simply continue with
 single dose of C vaccine (scenarios 1, 2) are least effective. Also,
cenarios continuing with C vaccine (scenarios 1, 2, 7, 8) always
ause ‘AWY’ strain replacement in the long-term (Table 3). Scenar-
os that continue with a single dose but switch to ACWY vaccine
scenarios 3, 4) also cause strain replacement, but it is slight and
ong-term (Table 3).
Age-speciﬁc projections for ‘Other’ and ‘AWY’ IMD  incidence for
cenario 6 are available in Supplementary File: Table S4. Vaccine
mpacts are most evident in vaccinated age groups, but indirectly7 (0.18, 0.76) 0.39 (0.06, 0.72) 0.37 (0.03, 0.72)
t t = 40, 50, 60, 75, and 90 years, with average and ± two standard deviations of 400
beneﬁt non-vaccinated age groups due to herd immunity (see also
Figs. 2 and 3).
To explore the impact of aggregating serogroups, we simulated
three ACWY vaccine scenarios using the alternative grouping A, C,
W135, Y (‘ACWY’) versus B and all other serogroups (‘Other’). Pre-
dictions are qualitatively unchanged, with all programs reducing
net IMD  incidence, and with similar relative effectiveness (Supple-
mentary File: Tables S5 and S6 and Fig. S1). Limited type B strain
replacement occurs, but is offset by steep declines in IMD  due to A,
C, W135, and Y. The relative increase in B and ungroupable preva-
lence is small – compared to the signiﬁcant relative decrease in C,
A, W and Y prevalence – simply because C, A, W and Y are much
less prevalent than ‘Other’ serogroups. Hence the ecological niche
that opens up for B and ungroupable serogroups when C, A, W and
Y are removed is relatively small.
4. Discussion
Our stochastic, two-strain dynamic model predicted that
switching from a monovalent C vaccine to a quadrivalent ACWY
vaccine while also adding a second dose to the immunization
schedule at 12 or 15 years of age provides the best long-term reduc-
tions in total IMD  incidence and prevents strain replacement to a
greater extent than continuing with a monovalent C vaccine pro-
gram.
Continuing with the current program of a single dose of
C vaccine provided the smallest reductions, and also induced
strain replacement of A, W135 and Y. However, this should not
be observed until at least 10 years after vaccination becomes
widespread. This is due to stochasticity, which masks the early
effects of replacement in IMD  data, though not necessarily in car-
riage data, which are less subject to stochasticity (Fig. 2d, inset).
In recent years, there is evidence of replacement at the carriage
level but not at the disease level [6,29], which is consistent with
these predictions. However, we  note there have been no conﬁrmed
examples of strain replacement at the time of publication.
Widespread strain replacement occurred with pneumococ-
cal vaccines, which stimulated the inclusion of more serogroups
in pneumococcal vaccines. However, the effect of pneumococcal
strain replacement on disease was highly variable, being much
more pronounced for some serotypes than others. Here, we  did
not explicitly allow serogroups to vary in their ability to cause
strain replacement, although some variability naturally emerged
out of the model’s transmission mechanisms. It remains to be seen
whether strain replacement will unfold for Nm vaccines, but the
similar biology of Nm and Streptococcus pneumonia, together with
our model projections, suggest it would not be surprising.Both vaccines are predicted to provide signiﬁcant herd immu-
nity, despite short-lived vaccine immunity. Under the alternative
grouping A, C, W,  Y versus B, ungroupable types, the ACWY vaccine
reduced ACWY IMD  incidence to almost zero (Fig. S1) and results
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Fig. 3. Model projections for scenario 5: vaccination of infants at 12 months, using the C vaccine (at t = 40–49 years), then infant vaccination with adolescent booster at 12
years  using the ACWY vaccine (at t = 50 years). (a) Overall prevalence of Nm carriage due to ‘Other’, (b) overall incidence of IMD due to ‘Other’, (c) overall prevalence of Nm
carriage due to ‘AWY’, (d) overall incidence of IMD  due to ‘AWY’, (e) age-stratiﬁed prevalence of Nm carriage due to ‘Other’, (f) age-stratiﬁed incidence of IMD  due to ‘Other’,
(g)  age-stratiﬁed prevalence of Nm carriage due to ‘AWY’, (h) age-stratiﬁed incidence of IMD  due to ‘AWY’. For plots (a–d), black lines represent the average of 400 Monte
Carlo  realizations, while the gray lines bound 2 standard deviations. For age-stratiﬁed plots (e–h), lines represent the average of 400 Monte Carlo realizations among those
age  0–4 years (blue line), 5–9 years (red line), 10–14 years (yellow line), 15–19 years (orange line), and ≥20 years (green line). The carriage time series appears smooth
because we present the average of many stochastic realizations.
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Table 3
Projected total IMD  Incidence due to ‘Other’ and ‘AWY’ infections, under all vaccine program scenarios and across all age classes.a
Scenario t = 40 t = 50 t = 60 t = 75 t = 90
Other
1 0.74 (0.24, 1.25) 0.58 (0.18, 0.99) 0.55 (0.14, 0.95) 0.51 (0.11, 0.91) 0.49 (0.89, 0.09)
2  0.73 (0.26, 1.21) 0.58 (0.18, 0.99) 0.53 (0.12, 0.94) 0.5 (0.09, 0.9) 0.47 (0.07, 0.86)
3  0.72 (0.24, 1.21) 0.59 (0.17, 1.01) 0.5 (0.12, 0.89) 0.49 (0.11, 0.88) 0.5 (0.12, 0.88)
4  0.73 (0.26, 1.2) 0.59 (0.17, 1.01) 0.5 (0.12, 0.88) 0.49 (0.09, 0.89) 0.5 (0.07, 0.93)
5  0.73 (0.26, 1.2) 0.59 (0.19, 0.99) 0.36 (0.04, 0.67) 0.28 (−0.04, 0.59) 0.27 (−0.06, 0.6)
6  0.73 (0.25, 1.21) 0.58 (0.19, 0.98) 0.3 (0.03, 0.58) 0.22 (−0.05, 0.49) 0.2 (−0.08, 0.48)
7  0.73 (0.26, 1.2) 0.58 (0.17, 1) 0.42 (0.08, 0.75) 0.32 (−0.01, 0.65) 0.27 (−0.03, 0.56)
8  0.73 (0.24, 1.21) 0.59 (0.17, 1) 0.37 (0.06, 0.68) 0.26 (−0.02, 0.55) 0.22 (−0.05, 0.49)
9  0.73 (0.24, 1.22) 0.58 (0.19, 0.97) 0.38 (0.08, 0.67) 0.3 (−0.01, 0.62) 0.29 (−0.05, 0.62)
10  0.72 (0.27, 1.18) 0.58 (0.18, 0.99) 0.33 (0.05, 0.61) 0.26 (−0.04, 0.56) 0.23 (−0.07, 0.54)
AWY
1  0.18 (0.01, 0.34) 0.19 (0.02, 0.36) 0.22 (0.03, 0.41) 0.25 (0.05, 0.45) 0.27 (0.05, 0.49)
2  0.17 (0.02, 0.33) 0.19 (0.02, 0.37) 0.24 (0.05, 0.44) 0.3 (0.08, 0.52) 0.32 (0.1, 0.54)
3  0.18 (0.01, 0.34) 0.19 (0.03, 0.35) 0.15 (0.01, 0.3) 0.13 (−0.01, 0.26) 0.1 (−0.03, 0.24)
4  0.17 (0.02, 0.33) 0.2 (0.02, 0.37) 0.15 (0.01, 0.3) 0.11 (−0.01, 0.23) 0.08 (−0.03, 0.2)
5  0.17 (0.01, 0.33) 0.19 (0.01, 0.37) 0.1 (0, 0.21) 0.05 (−0.02, 0.12) 0.03 (−0.03, 0.08)
6  0.17 (0.01, 0.34) 0.19 (0.02, 0.35) 0.09 (−0.01, 0.19) 0.04 (−0.03, 0.11) 0.02 (−0.03, 0.08)
7  0.18 (0.02, 0.34) 0.18 (0.01, 0.35) 0.24 (0.04, 0.44) 0.35 (0.1, 0.6) 0.4 (0.13, 0.67)
8  0.17 (0.02, 0.33) 0.19 (0.02, 0.35) 0.25 (0.04, 0.46) 0.38 (0.12, 0.64) 0.43 (0.16, 0.71)
9  0.17 (0.02, 0.33) 0.19 (0.02, 0.36) 0.16 (0.01, 0.3) 0.14 (−0.01, 0.28) 0.14 (−0.03, 0.3)
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a IMD  incidence (per 100,000 population per year) due to ‘Other’ serogroups at t =
ealizations.
re similar with a monovalent C vaccine. This is consistent with
he Canadian experience of signiﬁcant reductions in IMD due to
erogroup C after expanding vaccination coverage with a C vaccine
6].
Our model makes several simplifying assumptions that war-
ant discussion. For instance, almost all models of multivalent
accines assume some level of aggregation of different strains
30,31]. Our model combined B and ungroupable serogroups in
he ‘Other’ category. Hence, the baseline model could not cap-
ure potential serogroup B strain replacement caused by C and
CWY vaccines. However, our sensitivity analysis using the alter-
ative grouping explored this, ﬁnding no qualitative change in
ur prediction of ACWY vaccine impact. The robustness of our
esults to aggregation may  be rooted in the fact that serogroup
 tends to be less pathogenic on average than A, C, W135 and
 (Supplementary File: Fig. S2). Hence, using an ACWY vac-
ine replaces more pathogenic serogroups with a less pathogenic
erogroup, which should always result in net reductions in IMD
ncidence.
Aggregating tends to create an artiﬁcial ‘superbug’ that is harder
o eradicate in model simulations that the real-world individual
erogroups would be [32]. Also, we included short-lived natural
mmunity, which lessens the predicted impact of vaccines com-
ared neglecting natural immunity [33]. Hence, our results may  be
onservative with respect to vaccine impact. Finally, we assumed
he vaccine provides high protection against carriage. However,
ess is known about meningococcal vaccine efﬁcacy against car-
iage, in contrast to the vaccine’s demonstrated efﬁcacy against
MD. Another interesting aspect that we did not explore in this
aper is population attitudes toward meningococcal vaccines and
ow they inﬂuence vaccine uptake.
Our model is stochastic, allowing it to capture the intermittent,
utbreak nature of IMD. Future research may  support model vali-
ation by testing the model against IMD  outbreak data. This would
lso allow including outbreak control costs in future economic anal-
ses, which have largely been ignored to date.
The epidemiology of meningococcal disease is characterized by
ndemicity associated with a large variety of different clones, and
utbreaks of variable duration caused by a virulent clone. Envi-
onmental factors may  play a role in these features, or this may
ccur due to endogenous epidemiological effects [3]. In either case, (0.01, 0.27) 0.13 (−0.03, 0.3) 0.14 (−0.05, 0.33)
, 60, 75, and 90 years, with average and ± two standard deviations of 400 stochastic
such factors may  need to be accounted for in any model focusing
speciﬁcally on the nature of IMD  outbreaks.
Currently, only meningococcal conjugate vaccines against
serogroup C are in widespread use, although ACWY adolescent
vaccination is being adopted in many provinces. Our results sug-
gest that immunization programs employing quadrivalent ACWY
meningococcal vaccines instead may  have a much greater impact
on IMD  incidence. Additionally, epidemiologic simulations should
be followed by economic evaluations, which are required for
decision-making regarding new vaccination programs [34].
5. Conclusion
Switching from a monovalent C vaccine to a quadrivalent ACWY
vaccine in infants while also adding a second dose of ACWY vaccine
at 12 or 15 years of age is predicted to provide the best long-term
reductions in total IMD  incidence, and prevents strain replacement
to a greater extent than continuing with a monovalent C vaccine
program.
Conﬂict of interest
DV was  an employee of Pythagoras Consulting. AA is a former
employee of GlaxoSmithKline group of companies. PDW has
received research grants, honoraria and reimbursement of travel
expenses from the GlaxoSmithKline group of companies, Novar-
tis, Pﬁzer, Merck and Sanoﬁ Pasteur. ND is an employee of the
GlaxoSmithKline group of companies and has stock option in the
GlaxoSmithKline group of companies. CTB has received consulting
and research contracts from GlaxoSmithKline Biologicals SA. All
authors have submitted the ICMJE Form for Disclosure of Poten-
tial Conﬂicts of Interest. Conﬂicts that the editors consider relevant
to the content of the manuscript have been disclosed.
Authorship contributionAll authors contributed to conception and design of the study,
or acquisition of data, or analysis and interpretation of data; and
drafting the article or revising it critically for important intellectual
accine
c
m
A
o
f
(
V
P
u
s
A
A
i
0
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[D.M. Vickers et al. / V
ontent. All authors saw and approved the submitted version of the
anuscript.
cknowledgements
This work was supported by a research contract from Glax-
SmithKline Biologicals SA to Pythagoras Consulting (CTB). The
unders had no role in the research. We  thank Cédric Laloyaux
Business & Decision Life Sciences on behalf of GlaxoSmithKline
accines) for managing the publication and Yuan Tian and Keith
oore for assistance with computer programming. This work was
ndertaken while AA was a GlaxoSmithKline Vaccines employee;
he is now employed by Abbott Laboratories, Diagnostics Division,
bbott Park, IL, USA.
ppendix A. Supplementary data
Supplementary data associated with this article can be found,
n the online version, at http://dx.doi.org/10.1016/j.vaccine.2013.
9.034.
eferences
[1] Christensen H, May  M,  Bowen L, Hickman M,  Trotter CL. Meningococcal
carriage by age: a systematic review and meta-analysis. Lancet Infect Dis
2010;10:853–61.
[2] Trotter CL, Maiden MCJ. Meningococcal vaccines and herd immunity: lessons
learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines
2009;8:851–61.
[3] Stollenwerk N, Maiden MCJ, Jansen VAA. Diversity in pathogenicity can
cause outbreaks of meningococcal disease. Proc Natl Acad Sci USA
2004;101:10229–34.
[4] Tzeng YL, Stephens DS. Epidemiology and pathogenesis of Neisseria meningidi-
tis.  Microbes Infect 2000;2:687–700.
[5] Pollard AJ, Frasch C. Development of natural immunity to Neisseria meningi-
tides. Vaccine 2001;19:1327–46.
[6] Bettinger JA, Scheifele DW,  LeSaux N, Halperin S, Vaudry W,  Tsang R. The
impact of childhood meningococcal serogroup C conjugate vaccine programs
in  Canada. Pediatr Infect Dis J 2009;28(3):220–4.
[7] Martcheva M,  Bolker BM,  Holt RD. Vaccine-induced pathogen strain replace-
ment: what are the mechanisms? J Roy Soc Interface 2008;5:3–13.
[8] NACI. Update on the invasive meningococcal disease and meningococ-
cal vaccine conjugate recommendations. Canada Communicable Disease
Report 35; 2009 http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/
acs-dcc-3/index-eng.php
[9] Trotter CL, Gay NJ, Edmunds WJ.  Dynamic models of meningococcal carriage,
disease and the impact of serogroup C conjugate vaccination. Am J Epidemiol
2005;162:89–100.
10] Guzzetta G, Manfredi P, Gasparini R, Panatto D, Edmunds WJ.  On the relation-
ship between meningococcal transmission dynamics and disease: remarks on
humoral immunity. Vaccine 2009;27:3429–34.11] Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup
B  vaccine combined with out membrane vesicles. Expert Opin Biol Ther
2011;11(7):969–85.
12] Muzzi A, Mora M,  Pizza M,  Rappuoli R, Donati C. Conservation of meningococcal
antigens in the genus Neisseria. mBio 2013;4(3):e00163–213.
[
[ 33 (2015) 268–275 275
13] Andersson H, Britton T. Stochastic epidemic models and their statistical
analysis. New York: Springer Verlag; 2000.
14] Statistics Canada. Vital statistics; 2012 [accessed 16.07.12] http://www.
statcan.ca
15] PHAC. Invasive meningococcal disease in Canada, 1 January 1997 to 31
December 1998; 2000. p. 26–31. Canadian Communicable Disease Monthly
Report.
16] PHAC. Enhanced surveillance of invasive meningococcal disease in Canada, 1
January 1999 through 31 December 2001; 2004. p. 30. Canadian Communicable
Disease Monthly Report.
17] PHAC. Canadian Immunization Guide. 7th ed; 2006 [accessed 16.07.12]
http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-meni-eng.php
18] PHAC. Enhanced surveillance of invasive meningococcal disease in Canada, 1
January 2002 through 31 December 2003, 32(8); 2006. Canadian Communica-
ble  Disease Monthly Report.
19] PHAC. Enhanced surveillance of invasive meningococcal disease in Canada, 1
January 2004 through 31 December 2005, 33(10); 2007. Canadian Communi-
cable Disease Monthly Report.
20] PHAC. Advice for consideration of quadrivalent (A, C, Y, W-135) meningococcal
conjugate vaccine, for use by provinces and territories, 3562(Suppl.); 2010.
Canadian Communicable Disease Monthly Report.
21] Patrick DM,  Champagne S, Goh SH, Arsenault G, Thomas E, Shaw C, et al. Neisse-
ria meningitidis carriage during an outbreak of Serogroup C disease. Clin Infect
Dis 2003;37(9):1183–8.
22] DeWals P, Bouckaert A. Methods for estimating the duration of bacterial car-
riage. Int J Epidemiol 1985;14:628–34.
23] Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal
disease. N Engl J Med  2001;344:1378–88.
24] Goldschneider I, Gotschlich EC, Artenstein MS.  Human immunity to
the  meningococcus: development of natural immunity. J Exp Med
1969;129:1327–48.
25] Campbell H, Andrews N, Borrow R, Trotter CL, Miller E. Updated post-
licensure surveillance of meningococcal C conjugate vaccine in England and
Wales: effectiveness, validation of serological correlate of protection and
modelling predictions of the duration of herd immunity. Clin Vacc Immunol
2010;17(5):840–7.
26] Mossong J, Hens N, Jit M,  Beutels P, Auranen K, Mikolajczyk R, et al. Social
contacts and mixing patterns relevant to the spread of infectious diseases. PLoS
Med  2008;5(3):e74.
27] White CP, Scott J. Meningococcal Serogroup C conjugate vaccination in Canada:
how far have we progressed? How  far do we have to go? Can J Public Health
2010;101(1):12–4.
28] Boulianne N, Bradet R, Audet D. Enquête sur la couverture vaccinale des
enfants de 1 an et 2 ans au Québec en 2010. Québec: Institut national de
santé publique du Québec; 2011 http://www.inspq.qc.ca/pdf/publications/
1318 EnqueteCouvVaccinEnfants1Et2AnsQc2010.pdf
29] Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate
vaccine: the experience in England and Wales. Vaccine 2009;27(Suppl. 2):
B20–9.
30] Dasbach E, Elbasha E, Insinga R. Mathematical models for predicting the epi-
demiologic and economic impact of vaccination against human papillomavirus
infection and diseases. Epidemiol Rev 2006;28(1):88–100.
31] Tully S, Anonychuk AM,  Sanchez DM,  Galvani AP, Bauch CT. Time for change? An
economic evaluation of integrated cervical screening and HPV  immunization
programs in Canada. Vaccine 2012;30:425–35.
32] van de Velde N, Brisson M,  Boily M.  Understanding differences in predictions
of  HPV vaccine effectiveness: a comparative model-based analysis. Vaccine
2010;28(33):5473–84.33] Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: modelling the impact
of  HPV vaccines on cervical cancer and screening programmes. Vaccine
2006;24(Suppl. 3):S178–86.
34] Erickson LJ, DeWals P, Farand L. An analytical framework for immunization
programs in Canada. Vaccine 2005;23(19):2468–74.
